Table 1. Clinical features of patients at baseline and during the course of the treatment.
| Baseline | HBsAg (log IU/ml) | Anti-HBs Ab status | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case # | Group | Age (year) | Sex | Analog | HBV DNA (IU/ml) | AST (IU/ml) | ALT (IU/ml) | Metavir activity | Metavir fibrosis | W0 | W12 | W24 | W48 | W96 | W144 | W0 | W48 | W96 | W144 |
| 1 | NA | 55 | M | tenofovir | <20 | 22 | 21 | 2 | 4 | 2,85 | 2,97 | 2,93 | 2,89 | 2,83 | ND | neg | neg | neg | neg |
| 2 | 54 | M | entecavir | <20 | 27 | 24 | 1 | 1 | 3,17 | 3,15 | 3,16 | 3,02 | 2,82 | ND | neg | neg | neg | neg | |
| 3 | 56 | M | tenofovir | <20 | 38 | 54 | ND | 4 | 1,72 | 1,72 | 1,72 | 1,65 | 1,60 | ND | neg | neg | neg | neg | |
| 4 | 34 | M | entecavir | <20 | 27 | 51 | 1 | 0 | 3,71 | 3,74 | 3,51 | 3,54 | 3,49 | ND | neg | ND | neg | ND | |
| 5 | 31 | M | tenofovir | <20 | 28 | 28 | 1 | 0 | 4,07 | 3,97 | 3,99 | 4,13 | 3,98 | ND | neg | neg | neg | ND | |
| 6 | 51 | M | tenofovir | <20 | 22 | 35 | ND | ND | 3,08 | 2,99 | 3,04 | 3,05 | 3,05 | 2,80 | neg | ND | neg | neg | |
| 7 | 39 | M | entecavir | <20 | 19 | 51 | 3 | 3 | 3,11 | 3,08 | 3,13 | 3,11 | 3,09 | 2,92 | neg | neg | neg | neg | |
| 8 | 54 | M | tenofovir | <20 | 23 | 29 | 2 | 2 | 3,41 | 3,32 | 3,34 | 3,16 | 3,08 | ND | neg | ND | neg | neg | |
| 9 | 35 | M | tenofovir | <20 | 35 | 38 | 2 | 4 | 3,39 | 3,28 | 3,36 | 3,19 | 3,12 | ND | neg | neg | neg | ND | |
| 10 | 48 | F | lamivudine | <20 | 19 | 15 | 3 | 1 | 2,60 | 2,55 | 2,38 | 2,56 | 2,51 | 2,24 | neg | neg | neg | neg | |
| 11 | 65 | M | tenofovir | <20 | 30 | 25 | 1 | 4 | 0,61 | 0,61 | 0,18 | 0,18 | -0,52 | ND | neg | neg | neg | pos | |
| 12 | 37 | M | entecavir | <20 | 43 | 35 | 2 | 1 | 4,32 | 4,30 | 4,21 | 4,14 | 4,42 | ND | neg | neg | neg | ND | |
| 13 | 62 | F | lamivudine | <20 | 23 | 19 | 1 | 2 | 3,36 | ND | 3,40 | 3,22 | 3,35 | ND | neg | neg | neg | neg | |
| 14 | 35 | M | tenofovir | <20 | 24 | 24 | 2 | 4 | 3,51 | 3,44 | 3,50 | 3,57 | 3,47 | 3,54 | neg | neg | neg | ND | |
| 15 | NA + Peg-IFN-α | 41 | M | entecavir | <20 | 28 | 39 | 3 | 2 | 3,66 | 3,55 | 3,53 | 3,00 | 3,53 | 3,37 | neg | neg | neg | neg |
| 16 | 44 | M | entecavir | <20 | 23 | 41 | 1 | 2 | 3,35 | 3,21 | 3,24 | 3,10 | 3,36 | ND | neg | neg | neg | neg | |
| 17 | 63 | M | tenofovir | <20 | 31 | 42 | 1 | 1 | 2,93 | 2,97 | 2,83 | 2,59 | 2,65 | ND | neg | neg | neg | ND | |
| 18 | 57 | M | entecavir | <20 | 19 | 28 | 2 | 4 | 2,88 | 2,89 | 2,79 | 2,67 | 2,61 | 2,34 | neg | neg | neg | neg | |
| 19 | 49 | M | entecavir | <20 | 32 | 20 | ND | ND | 3,90 | 3,78 | 2,70 | 1,28 | 3,26 | 2,90 | neg | neg | neg | neg | |
| 20a | 49 | F | tenofovir | <20 | 17 | 13 | 1 | 2 | 2,38 | 2,24 | 2,36 | 2,20 | 1,61 | ND | neg | neg | neg | ND | |
| 21 | 67 | M | tenofovir | <20 | 40 | 56 | 2 | 2 | 3,78 | 3,64 | 3,24 | 1,83 | 3,08 | 3,06 | neg | neg | neg | neg | |
| 22 | 34 | M | entecavir | <20 | 24 | 22 | ND | ND | 4,36 | 4,27 | 4,27 | 4,34 | 4,35 | ND | neg | neg | neg | ND | |
| 23 | 61 | M | adefovir | <20 | 25 | 25 | 2 | 4 | 2,89 | 2,84 | 2,31 | 2,21 | 1,86 | ND | neg | neg | ND | ND | |
a: patient stopped treatment after W12
NA: nucleos(t)ide analog; ND: not determined